CompletedPhase 2

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

United States18 participantsStarted 2007-07-27

Plain-language summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with docetaxel may kill more tumor cells. PURPOSE: This phase II trial is studying giving sorafenib together with docetaxel to see how well it works in treating patients with metastatic androgen-independent prostate cancer.

Who can participate

Age range18 Years – 120 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. increasing serum PSA levels on at least two measurements at least two weeks apart.
✓. Progressive measurable disease (by RECIST criteria) independent of PSA
✓. Bone scan progression with at least one new lesion.

What they're measuring

Prostate Specific Antigen (PSA) Response Rate

Timeframe: From start of treatment until withdrawal from the study, approximately 12 months

Trial details

NCT IDNCT00589420

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-02-02

Results submitted2020-09-24

View on ClinicalTrials.gov More Prostate Cancer trials